LARGE-SCALE CLINICAL AND POPULATION-BASED RESEARCH
Professor Christopher Reid,
Cardiovascular Epidemiologist & Research Professor, School of Public Health & Preventive Medicine, Monash University, Victoria, Australia & School of Population Health at Curtin University, Western Australia & Chair, Australian Clinical Trials Alliance (ACTA)
RESEARCHER PROFILE
Filmed in Perth, Australia | October 2026
Christopher Reid is an internationally renowned cardiovascular epidemiologist with appointments as a Research Professor in both the School of Population Health at Curtin University and the School of Public Health and Preventive Medicine, at Monash University.
He was re-appointed as a John Curtin Distinguished Professor in 2021 and is currently Director of the Monash and Curtin Centre for Clinical Research and Education (CCRE). He has been awarded over $178M as a Chief Investigator and has received continuous NHMRC funding since 2001.
His major research interests include clinical outcome registries, randomised controlled trials, and epidemiological cohort studies. He has over 820 peer-reviewed publications (with over 44000 citations and a H-Index of 91) many of which are in leading journals including the New England Journal of Medicine, the Lancet, JAMA, JACC, and the BMJ.
He is a Chief Investigator for the Colchicine in Type 2 diabetes trial (COLCOT-T2D), the Aspirin in the Elderly (ASPREE) trial, the HOPE-3 trial, the Statins in Reducing Events in the Elderly (STAREE) trial and the LEADER-PAD trial. He is also the research director for the Australian and New Zealand Cardiothoracic database (ANZSCTS) registry and the Victorian Cardiac Outcomes registry (VCOR).
He is the Board Chair of the Australian Clinical Trials Alliance (ACTA) and a board member of the Australian New Zealand Alliance for Cardiovascular Trials (ANZACT) Network and the Australian Cardiovascular Alliance (ACVA).
Prof Reid has trained more than 30 PhD students to completion and undertaken assignments for the World Health Organization in cardiovascular disease prevention in the Asia Pacific Region.
Source: Supplied
You Might also like
-
Vision impairment in children and the impact on children and their families
Dr Sue Silveira holds a conjoint academic position with Macquarie University and is the Course Director for their Master of Disability Studies, which is administered and delivered by NextSense Institute in affiliation with the University. She teaches in the areas of vision impairment and disability, and aims to share her knowledge while learning from others, especially people who are blind or have low vision and their families.
-
Novel immunotherapies in lymphoma
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
https://orcid.org/0000-0001-9173-3944